1. Efficacy of downtitration or treatment withdrawal compared with continuous dosing after successful treatment with baricitinib in patients with moderate-to-severe atopic dermatitis in a randomized substudy from the long-term extension study BREEZE-AD3. (17th November 2022) Authors: Reich, Kristian; Simpson, Eric; Wollenberg, Andreas; Bissonnette, Robert; Abe, Masatoshi; Cardillo, Tracy; Janes, Jonathan; Sun, Luna; Chen, Sherry; Silverberg, Jonathan I Journal: British journal of dermatology Issue: Volume 188:Number 2(2023) Page Start: 208 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Safety of baricitinib for the treatment of atopic dermatitis over a median of 1.6 years and up to 3.9 years of treatment: an updated integrated analysis of eight clinical trials. (31st December 2023) Authors: Bieber, Thomas; Katoh, Norito; Simpson, Eric L.; de Bruin-Weller, Marjolein; Thaçi, Diamant; Torrelo, Antonio; Sontag, Angelina; Grond, Susanne; Issa, Maher; Lu, Xiaoyu; Cardillo, Tracy; Holzwarth, Katrin; Thyssen, Jacob P. Journal: Journal of dermatological treatment Issue: Volume 34:Number 1(2023) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗